672 Phase I clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in patients with recurrent ovarian cancer (OVCA)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.